321
Participants
Start Date
August 7, 2013
Primary Completion Date
March 11, 2016
Study Completion Date
March 2, 2017
Ranibizumab
Intravitreal injection of 0.5 mg ranibizumab
Verteporfin PDT
Infusion of 30 ml verteporfin in 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
Sham PDT
Infusion of 30 ml 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
Novartis Investigative Site, Taipei
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Taipei
Novartis Investigative Site, Taipei
Novartis Investigative Site, Seongnam-si
Novartis Investigative Site, Taoyuan District
Novartis Investigative Site, Petaling Jaya
Novartis Investigative Site, Changhua
Novartis Investigative Site, Batu Caves
Novartis Investigative Site, Kaohsiung City
Novartis Investigative Site, Songkhla
Novartis Investigative Site, Singapore
Novartis Investigative Site, Singapore
Novartis Investigative Site, Singapore
Novartis Investigative Site, Hong Kong
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Fukushima
Novartis Investigative Site, Maebashi
Novartis Investigative Site, Amagasaki
Novartis Investigative Site, Kobe
Novartis Investigative Site, Kobe
Novartis Investigative Site, Inashiki-gun
Novartis Investigative Site, Kita-gun
Novartis Investigative Site, Sakyo-ku
Novartis Investigative Site, Tsu
Novartis Investigative Site, Okayama
Novartis Investigative Site, Hirakata
Novartis Investigative Site, Osaka
Novartis Investigative Site, Osaka
Novartis Investigative Site, Ohtsu-city
Novartis Investigative Site, Bunkyo Ku
Novartis Investigative Site, Chiyoda-ku
Novartis Investigative Site, Mitaka
Novartis Investigative Site, Shinjuku Ku
Novartis Investigative Site, Chiba
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY